High-Dose Naxitamab (Humanized-3F8) PLUS Stepped-up Dosing of Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma: Outpatient Treament Low Immunogenicity, and Major Responses in a Phase II Trial
PEDIATRIC BLOOD & CANCER（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要